Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin—a hormone in the brain associated with empathy—offers promise for addressing a key symptom among ...

About 45% of children who receive intranasal midazolam for laceration repair do not respond to the medication and demonstrate ...

Tiziana Life Sciences, Ltd. has entered into a product development services agreement with Renaissance Lakewood LLC to enhance and scale up the formulation of its lead candidate, intranasal ...

The following is a summary of “Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V ...

Long COVID is a complex and often debilitating complication following COVID-19 infection. It affects millions worldwide, presenting with symptoms such as persistent fatigue, cognitive impairment ...

Alternative dosing routes, such as rectal and intranasal (IN) routes, have been suggested as options for oral or intravenous administration. Rhinitis and pharmacological agents used for treatment ...

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced its participation at the Emergencies ...